9/24/2012 9:20:05 AM
DURHAM, N.C.--(BUSINESS WIRE)--HyperBranch Medical Technology, Inc. announced today that it has completed patient enrollment in the AdherusTM Dural Sealant U.S. pivotal clinical trial, a controlled, randomized trial comparing the AdherusTM Dural Sealant in neurosurgery patients, to the only other approved sealant for these procedures. Over 240 patients were treated in the trial. Patients will be followed for four months to evaluate the safety and effectiveness of Adherus, following which, the data will be submitted to the FDA for review as part of the PMA submission.
comments powered by